Systemic MCPIP1 deficiency in mice impairs lipid homeostasis

Curr Res Pharmacol Drug Discov. 2020 May 6:1:1-9. doi: 10.1016/j.crphar.2020.03.001. eCollection 2020 Apr.

Abstract

Atherosclerosis involves interactions between inflammation system and dyslipidemia. MCPIP1 (Monocyte Chemotactic Protein induced Protein-1) is induced by proinflammatory molecules and serves as a negative feedback loop in regulating inflammatory responses. Our current study was designed to test the role of MCPIP1 in maintaining lipid homeostasis, the latter a pivotal factor that contributes to the pathogenesis of atherosclerosis. We found that MCPIP1 knockout mice displayed a decrease in levels of serum HDL-cholesterol and total triglycerides but an increase in serum LDL/VLDL-cholesterol levels when compared to wild-type mice. Additionally, ApoA-1 expression was reduced but LPL expression was upregulated in plasma from MCPIP1 knockout mice. The livers from the MCPIP1 knockout mice revealed a decrease in hepatocyte number and an increase in collagen deposition when compared to wild-type mice. These findings suggest that MCPIP1 deficiency can induce liver fibrosis, alter the expression of lipoproteins, and affect transportation and metabolism of lipids, indicating that MCPIP1 is involved in maintaining lipid homeostasis, possibly via negatively regulating inflammatory responses.

Keywords: ApoA-1, apoprotein A1; ApoB-100, apoprotein B100; Atherosclerosis; Dyslipidemia; IL-1 β , interleukin 1 beta; IL-6, interleukin 6; Lipoproteins; Liver; MCP-1, monocyte chemoattractant protein 1; MCPIP1 knockout; MCPIP1, Monocyte Chemotactic Protein induced Protein-1; TNF- α , Tissue necrosis factor alpha.